Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Vaccines. 2003 Oct;2(5):661-72.

Hepatitis A and considerations regarding the cost-effectiveness of vaccination programs.

Author information

  • 1Department of Internal Medicine University Of Alabama at Birmingham, Birmingham, AL 35294, USA.

Abstract

Hepatitis A vaccines have demonstrated a high degree of immunogenicity and an excellent safety profile. Immunization of certain populations and patient subgroups is recommended according to specific epidemiological and clinical factors, such as a greater likelihood of acquisition of infection or concerns regarding the risk of development of fulminant hepatitis and death. Therefore, the economic implications of routine and/or targeted vaccination programs in the general population and high-risk individuals have been examined. In this manuscript, the available data from the literature regarding the cost-effectiveness of hepatitis vaccination programs in healthy individuals and in those with chronic liver disease are reviewed.

PMID:
14711327
DOI:
10.1586/14760584.2.5.661
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center